Does a relationship exist between trends in estrogen receptor levels and breast cancer incidence and mortality?

1998 ◽  
Author(s):  
E Celentano ◽  
M Montella ◽  
P Bonelli ◽  
L Cecco ◽  
M De Marco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Incidence And Mortality

Major changes in breast cancer incidence in the United States over the period 2002 to 2004

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 1533-1533
Author(s):  
P. Ravdin ◽  
K. A. Cronin ◽  
N. Howlader ◽  
C. D. Berg ◽  
E. J. Feuer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Incidence Data ◽  
Incidence And Mortality ◽  
The Us ◽  
The Impact

1533 Background: We have recently reported that a steep decrease in the incidence of breast cancer occurred in the United States in 2003 relative to 2002 (BCRT 100: S5, 2006). This decrease was most evident in patients older than 50, and largely occurred because of a decrease in the incidence of estrogen receptor positive breast cancer. This decrease occurred after the report in 2002 of the results of first of the Women s Health Initiative trials of postmenopausal hormone therapy (HT). This publication showed that use of a combined estrogen/progestin combination was associated with increased risk of breast cancer and heart disease and led to an immediate and substantial decrease in the use of HT in the US. Dramatic shifts in breast cancer incidence are unusual, and provide unique opportunities to test models that have been developed to explain trends in breast cancer incidence and mortality. We have been engaged in modeling trends in breast cancer incidence and mortality, in collaborative effects such as the Cancer Intervention and Surveillance Modeling Network (CISNET), to understand these and other processes (NEJM 353:1784–1792,2005). These models have practical implications for understanding the impact of changes in risk factors, use of prevention strategies, screening, and treatment of breast cancer. Methods: SEER public use incidence data from 1990 to the end of 2003 will be updated with information from the release in the spring of 2007 of incidence data for 2004. We will analyze the full data set through 2004 and report on the trends in incidence of breast cancer in the population as a whole and by subsets (such as age, estrogen receptor status, stage etc). We will also use the most recent and detailed data about HT use and screening mammography during this period as part of modeling. Results: We are awaiting SEER data from 2004 which will be released by April of 2007. Conclusions: Our first SEER based multi-year analysis of breast cancer incidence following the change in HT use in the US will be presented. Modeling of these trends in incidence will be discussed in the context of understanding the role of various contributors to the change in breast cancer incidence and what insights on the evolution of preclinical disease might be possible. No significant financial relationships to disclose.

Breast Cancer

2018 ◽  
Author(s):  
Nancy E Davidson
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Replacement ◽  
Breast Cancer Incidence ◽  
Stage Iv ◽  
The United States ◽  
Rate Of Increase ◽  
Stage Iv Breast Cancer ◽  
Incidence And Mortality

Invasive breast cancer, the most common nonskin cancer in women in the United States, will be diagnosed in 266,120 In 2018, along with 63,960 new cases of non-invasive (in situ) breast cancer. Incidence and mortality reached a plateau and appear to be dropping in both the United States and parts of western Europe. This decline has been attributed to several factors, such as early detection through the use of screening mammography and appropriate use of systemic adjuvant therapy, as well as decreased use of hormone replacement therapy. However, the global burden of breast cancer remains great, and global breast cancer incidence increased from 641,000 in 1980 to 1,643,000 in 2010, an annual rate of increase of 3.1%. This chapter examines the etiology, epidemiology, prevention, screening, staging, and prognosis of breast cancer. The diagnoses and treatments of the four stages of breast cancer are also included. Figures include algorithms used for the systemic treatment of stage IV breast cancer and hormone therapy for women with stage IV breast cancer. Tables describe selected outcomes from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 chemoprevention trials, tamoxifen chemoprevention trials for breast cancer, the TNM staging system and stage groupings for breast cancer, some commonly used adjuvant chemotherapy regimens, an algorithm for suggested treatment for patients with operable breast cancer from the 2011 St. Gallen consensus conference, guidelines for surveillance of asymptomatic early breast cancer survivors from the American Society of Clinical Oncology, and newer agents for metastatic breast cancer commercially available in the United States. This review contains 2 highly rendered figures, 8 tables, and 108 references.

Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome

2019 ◽  
Vol 177 (1) ◽  
pp. 77-91
Author(s):  
Cody Plasterer ◽  
Shirng-Wern Tsaih ◽  
Amy R. Peck ◽  
Inna Chervoneva ◽  
Caitlin O’Meara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study

2019 ◽  
Vol 37 (21) ◽  
pp. 1800-1809 ◽  
Author(s):  
Thomas P. Ahern ◽  
Anne Broe ◽  
Timothy L. Lash ◽  
Deirdre P. Cronin-Fenton ◽  
Sinna Pilgaard Ulrichsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Dibutyl Phthalate ◽  
Cox Regression ◽  
Breast Cancer Incidence ◽  
Drug Products ◽  
Phthalate Exposure ◽  
Long Term Treatment ◽  
High Level

PURPOSE Phthalate exposure is ubiquitous and especially high among users of drug products formulated with phthalates. Some phthalates mimic estradiol and may promote breast cancer. Existing epidemiologic studies on this topic are small, mostly not prospective, and have given inconsistent results. We estimated associations between longitudinal phthalate exposures and breast cancer risk in a Danish nationwide cohort, using redeemed prescriptions for phthalate-containing drug products to measure exposure. METHODS We ascertained the phthalate content of drugs marketed in Denmark using an internal Danish Medicines Agency ingredient database. We enrolled a Danish nationwide cohort of 1.12 million women at risk for a first cancer diagnosis on January 1, 2005. By combining drug ingredient data with the Danish National Prescription registry, we characterized annual, cumulative phthalate exposure through redeemed prescriptions. We then fit multivariable Cox regression models to estimate associations between phthalate exposures and incident invasive breast carcinoma according to tumor estrogen receptor status. RESULTS Over 9.99 million woman-years of follow-up, most phthalate exposures were not associated with breast cancer incidence. High-level dibutyl phthalate exposure (≥ 10,000 cumulative mg) was associated with an approximately two-fold increase in the rate of estrogen receptor–positive breast cancer (hazard ratio, 1.9; 95% CI, 1.1 to 3.5), consistent with in vitro evidence for an estrogenic effect of this compound. Lower levels of dibutyl phthalate exposure were not associated with breast cancer incidence. CONCLUSION Our results suggest that women should avoid high-level exposure to dibutyl phthalate, such as through long-term treatment with pharmaceuticals formulated with dibutyl phthalate.

Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative

Cancer ◽  
2020 ◽  
Vol 126 (16) ◽  
pp. 3638-3647
Author(s):  
Kathy Pan ◽  
Rowan T. Chlebowski ◽  
Joanne E. Mortimer ◽  
Marc J. Gunther ◽  
Thomas Rohan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Insulin Resistance ◽  
Women's Health ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Women's Health Initiative ◽  
Health Initiative ◽  
Incidence And Mortality ◽  
The Women’S Health Initiative

scholarly journals Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases

BMJ Open ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. e028461 ◽  
Author(s):  
Kaimin Hu ◽  
Peili Ding ◽  
Yinan Wu ◽  
Wei Tian ◽  
Tao Pan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Cancer Incidence ◽  
Disease Incidence ◽  
Breast Cancer Incidence ◽  
Global Burden ◽  
Incidence And Mortality ◽  
Global Burden Of Diseases ◽  
Concentration Indices ◽  
Burden Of Diseases

ObjectivesDisparities in the global burden of breast cancer have been identified. We aimed to investigate recent patterns and trends in the breast cancer incidence and associated mortality. We also assessed breast cancer-related health inequalities according to socioeconomic development factors.DesignAn observational study based on the Global Burden of Diseases.MethodsEstimates of breast cancer incidence and mortality during 1990–2016 were obtained from the Global Health Data Exchange database. Subsequently, data obtained in 2016 were described using the age-standardised and age-specific incidence, mortality and mortality-to-incidence (MI) ratios according to sociodemographic index (SDI) levels. Trends were assessed by measuring the annual percent change using the joinpoint regression. The Gini coefficients and concentration indices were used to identify between-country inequalities.ResultsCountries with higher SDI levels had worse disease incidence burdens in 2016, whereas inequalities in the breast cancer incidence had decreased since 1990. Opposite trends were observed in the mortality rates of high and low SDI countries. Moreover, the decreasing concentration indices, some of which became negative, among women aged 15–49 and 50–69 years suggested an increase in the mortality burdens in undeveloped regions. Conversely, inequality related to the MI ratio increased. In 2016, the MI ratios exhibited distinct gradients from high to low SDI regions across all age groups.ConclusionsThe patterns and trends in breast cancer incidence and mortality closely correlated with the SDI levels. Our findings highlighted the primary prevention of breast cancer in high SDI countries with a high disease incidence and the development of cost-effective diagnostic and treatment interventions for low SDI countries with poor MI ratios as the two pressing needs in the next decades.

Sign in / Sign up

Export Citation Format

Share Document